A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
NCT ID: NCT02325050
Last Updated: 2017-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
164 participants
INTERVENTIONAL
2015-01-08
2017-05-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
NCT02313077
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
NCT02543268
A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
NCT02543567
A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.
NCT02326194
Experimental Ebola Vaccine Trial
NCT00072605
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Ad26. ZEBOV
One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
Placebo
One 0.5 mL IM injection of 0.9% saline.
Group 2
Participants will receive MVA-BN-Filo/Ad26.ZEBOV (Day 1 /Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Ad26. ZEBOV
One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
Placebo
One 0.5 mL IM injection of 0.9% saline.
Group 3
Participants will receive MVA-BN-Filo /Ad26.ZEBOV/ (Day 1/Day 57) or placebo (Day 1/Day 57). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Ad26. ZEBOV
One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
Placebo
One 0.5 mL IM injection of 0.9% saline.
Group 4
Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Ad26. ZEBOV
One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
Placebo
One 0.5 mL IM injection of 0.9% saline.
Group 5
Participants will receive MVA-BN-Filo (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Ad26. ZEBOV
One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
Placebo
One 0.5 mL IM injection of 0.9% saline.
Group 6
Participants will receive Ad26.ZEBOV (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive MVA-BN-Filo (1\*10\^8 TCID50) on Day 360.
MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Ad26. ZEBOV
One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
Placebo
One 0.5 mL IM injection of 0.9% saline.
Group 7
Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
Ad26. ZEBOV
One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Placebo
One 0.5 mL IM injection of 0.9% saline.
Group 8
Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1 /Day 29) or Placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (1x10\^11 vp) on Day 360.
MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Ad26. ZEBOV
One 0.5 mL IM injection of 1\*10\^11 viral particles (vp).
Placebo
One 0.5 mL IM injection of 0.9% saline.
Group 9
Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 8) or Placebo (Day 1/Day 8).
MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Ad26. ZEBOV
One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
Placebo
One 0.5 mL IM injection of 0.9% saline.
Group 10
Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15).
MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Ad26. ZEBOV
One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
Placebo
One 0.5 mL IM injection of 0.9% saline.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Ad26. ZEBOV
One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Ad26. ZEBOV
One 0.5 mL IM injection of 1\*10\^11 viral particles (vp).
Placebo
One 0.5 mL IM injection of 0.9% saline.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a body mass index (BMI) ≥18.5 and \<35.0 kg/m2
* Women of childbearing potential must have a negative serum β-human chorionic gonadotropin pregnancy test at screening, a negative urine pregnancy test immediately prior to each study vaccine administration, and practice adequate birth control measures from 28 days before the prime vaccination until at least 3 months after the boost vaccination as specified in the study protocol. If not heterosexually active at screening, must agree to practice adequate birth control measures if they become heterosexually active during their participation in the study (from screening onwards until at least 3 months after the boost vaccination). Agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during participation in the study (from screening onwards until at least 3 months after the boost vaccination)
* Women of non-childbearing potential, defined as postmenopausal (\>45 years of age with amenorrhea for ≥2 years or any age with amenorrhea for ≥6 months and serum follicle-stimulating hormone \[FSH\] \>40 mIU/mL) or surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), are not required to use the birth control methods as specified in the study protocol
* A man who has not had a vasectomy and is sexually active with a woman of childbearing potential must agree to use a double-barrier method of birth control, such as either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. In case the female partner is using an adequate method of birth control, a single-barrier method of birth control for the male subject is acceptable. Men must also agree not to donate sperm during their participation in the study (from screening onwards until at least 3 months after the boost vaccination)
* Must be available and willing to participate for the duration of the study visits and follow-up, provide verifiable identification, and have a means to be contacted
Exclusion Criteria
* Has been diagnosed with Ebola disease or exposed to Ebola including travel to West Africa in the last 12 months. West Africa includes but is not limited to the countries of Guinea, Liberia, Mali, and Sierra Leone. Participants who anticipate traveling to epidemic Ebola areas before the start of the long-term follow-up period will also be excluded from enrollment into the study
* Has received any Ad26- or MVA-based candidate vaccine in the past
* Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccines), including known allergy to egg or aminoglycosides
* A woman who is pregnant or breast-feeding, or planning to become pregnant while enrolled in the study or within 3 months after the boost vaccination
* History of diabetes mellitus type 1 or type 2, including cases controlled with diet alone; thyroidectomy, or thyroid disease requiring medication during the last 12 months; uncontrolled hypertension as defined in the study protocol; or, major psychiatric illness and/or substance abuse problems during the past 12 months that in the opinion of the investigator would preclude participation
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Vaccines & Prevention B.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen Vaccines & Prevention B.V. Clinical Trial
Role: STUDY_DIRECTOR
Janssen Vaccines & Prevention B.V.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rockville, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VAC52150EBL1002
Identifier Type: OTHER
Identifier Source: secondary_id
CR106479
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.